Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Will the Oral Vaccine Market Evolve in Terms of Growth and Size by 2029?
The market for oral vaccines has experienced substantial growth in the recent past. It is expected to expand from $3.59 billion in 2024 to $3.95 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. A variety of factors have contributed to this growth during the historic period, including increasing investment in research and development of vaccines, regulatory support for oral vaccine trials, a rise in international travel and tourism, the requirement for widespread immunization in the course of epidemics, and the development of cold chain infrastructure.
In the next few years, the oral vaccine market is anticipated to experience robust growth, expanding to a size of $5.74 billion in 2029 at a CAGR of 9.8%. This forecasted growth can be attributed to factors such as the increasing worldwide impact of infectious diseases, a rise in the preference for needle-free vaccine administration methods, higher rates of acceptance among pediatric patients, better patient compliance, and a surge in immunization programs initiated by governments. The forecast period is set to see several significant trends, including the advent of innovative oral vaccine technologies, advancements in the field of oral drug delivery, partnerships between public and private entities, developments in oral vaccines for diseases outside the traditional scope, and enhancements in encapsulation and formula crafting techniques.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27373&type=smp
What factors are expected to fuel Oral Vaccine market growth in the coming years?
The escalating incidence of transmissible diseases is predicted to fuel the progression of the oral vaccine market. Transmissible diseases, the result of harmful microscopic organisms like bacteria, viruses, fungi, or parasites, can easily be spread from person to person or through the environment. The upsurge in these diseases is credited to the rise in global travel, which facilitates the quick movement of both people and pathogens across countries, speeding up the dispersion of infections globally. Oral vaccines offer significant benefits for infectious diseases because they stimulate mucosal immunity in the gut, a common pathway for many pathogens, providing effective protection at the site of infection. For example, the Health Security Agency, a UK government body, reported in May 2025 that cases of tuberculosis (TB) in England showed an increase of 11.0% in 2023 compared to 2022. As a result, the escalating prevalence of infectious diseases is propelling the oral vaccine market’s growth.
What Are The Key Findings From The Segmentation Analysis Of The Oral Vaccine Market?
The oral vaccine market covered in this report is segmented
1) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Other Vaccine Types
2) By Application: Polio, Tuberculosis, Rabies, Influenza, Cholera, Other Applications
3) By End-User: Hospital , Clinics, Government Organization, Other End-Users
Subsegments:
1) By Live Attenuated Vaccines: Oral Polio Vaccine (OPV), Rotavirus Vaccine, Oral Typhoid Vaccine, Oral Cholera Vaccine
2) By Inactivated Vaccines: Inactivated Polio Vaccine (IPV), Inactivated Cholera Vaccine, Inactivated Hepatitis A Vaccine
3) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Vaccines, Conjugate Vaccines
4) By Other Vaccine Types: DNA Vaccines, RNA Vaccines, Virus-Like Particle (VLP) Vaccines, Recombinant Vector Vaccines
Which Trends Are Expected To Shape The Future Of The Oral Vaccine Market?
Leading organizations within the oral vaccine market are concentrating on the creation of novel products such as second-generation pill vaccines which aim to boost immune reactions and simplify administration. These second-generation oral vaccines in pill form are geared towards the enhancement of immunogenicity, expansion of protection, and facilitation of mass immunization that circumvent the necessity for needles or cold chain storage. For instance, in March 2025, a biotech firm from the U.S. known as Vaxart Inc. commenced a Phase 1 clinical trial for its upgraded oral norovirus vaccine which is administered via a pill. The clinical trial intends to gauge the enhanced immune responses and the vaccine’s safety features purposed to meet the continued worldwide demand for cost-effective and efficient norovirus immunization solutions. The pill-based approach eliminates challenges inherent to injectable vaccines, enabling quick and widespread distribution, especially in the event of an outbreak.
What Are The Most Active Companies In The Oral Vaccine Market Today?
Major companies operating in the oral vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Sinovac Biotech Ltd., Panacea Biotec Ltd., Emergent BioSolutions Inc., Zydus Lifesciences, Serum Institute of India Pvt. Ltd., Bharat Biotech Ltd., Adimmune, Haffkine Biopharmaceutical Co. Ltd., Changchun BCHT Biotechnology Co., BIBCOL, Medigen Vaccine Biologics Corp., BlueWillow Biologics Inc., BioNet Asia Co. Ltd., and Innovax.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/oral-vaccine-global-market-report
Which Regional Markets Are Attracting The Most Investment In Oral Vaccine?
North America was the largest region in the oral vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27373&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model